News & Events

Excellent news!
Press release (Source: Business Wire).
Nasdaq
WSJ

Interviews in Biopharma-Reporter and Labmanager portray Redbiotec and its innovative approach to novel vaccines. Redbiotec is also proud to announce that global player GE Healthcare presents Redbiotec as premium partner in the field of bio-production (watch video).

Redbiotec and the research group of Dr. Sallie Permar, MD PhD, Associate Professor of Pediatrics at Duke University School of Medicine, announce a collaboration to study the contribution of complex antigens to protective immunity against Cytomegalovirus (CMV). The goal of the study is to gain insights into the correlates of protection.

Redbiotec will provide proprietary CMV antigens to be tested in sera from a target patient population to identify immune responses that are important to be targeted by a CMV vaccine to protect against infant virus transmission. The studies with Dr. Permar as well as with Prof. Britt, announced in June this year, are part of Redbiotec’s track towards clinical validation of proprietary CMV vaccine candidates.

“GE Healthcare Life Sciences seeks to collaborate with world-wide biotechnology leaders such as Redbiotec to help drive disease research forward.” (Jakob Liderfelt, Section Manager Cell Culture, LS Bio Process GE Healthcare Life Sciences).
See article on Yahoo Finance. And GE Healthcare video statement.

Redbiotec announces today the appointment of Dr. Sallie Permar, MD PhD, Associate Professor of Pediatrics at Duke University School of Medicine, to Redbiotec’s Scientific Advisory Board.
Dr. Permar is a leading scientist studying neonatal viral pathogenesis including congenital Cytomegalovirus (CMV) infection. Dr. Permar and her team utilize nonhuman primate models and human cohort studies to understand and elicit immune responses that can prevent vertical virus transmission.
Redbiotec’s team has the goal to develop the first CMV vaccine on the market and we are glad that Dr. Permar will scientifically support Redbiotec in its efforts.